- Language: English
- 123 Pages
- Published: October 2012
- Region: Global
Global Biosimulation Market 2014-2018
- ID: 2711992
- November 2013
- Region: Global
- 62 pages
The analysts forecast the Global Biosimulation market to grow at a CAGR of 18.31 percent over the period 2013-2018. One of the key factors contributing to this market growth is the reduction in drug discovery and development costs, owing to the deployment of biosimulation solutions. The Global Biosimulation market has also been witnessing increasing collaborations and partnerships. However, issues associated with the accuracy in prediction, could pose a challenge to the growth of this market.
The report, the Global Biosimulation Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, the APAC region, and the ROW; it also covers the Global Biosimulation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Accelrys Inc., Certara L.P., Schrodinger Llc. and Simulation Plus Inc.
Other vendors mentioned in the report are Advanced Chemistry Development Inc., Archimedes Inc., Bayer Technology Services, Biomed Simulation Inc., Chemical Computing Group Inc., Compugen Ltd., Entelos Inc., Genedata AG, Immunetrix Inc., InhibOx Ltd., INOSIM Software GmbH, In Silico Biosciences Inc., Insilico Biotechnology AG, LeadInvent Technologies Pvt. Ltd., Leadscope Inc., Molecular Knowledge Systems Inc., Nimbus Discovery Llc, OpenEye Scientific Software Inc., Optimata Inc., Physiomics Plc, Rhenovia Pharma SAS, Synergix Ltd., and Vascular Sciences.
Key questions answered in this report:
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Application
08. Market Segmentation by Approach to Model Development
09. Market Segmentation by Scale of Biosimulation
10. Geographical Segmentation
10.1 Global Biosimulation Market Segmentation by Geography 2013-2018
10.2 Biosimulation Market in North America
10.2.1 Market Size and Forecast
10.3 Biosimulation Market in Europe
10.3.1 Market Size and Overview
10.4 Biosimulation Market in APAC
10.4.1 Market Size and Overview
10.5 Biosimulation Market in ROW
10.5.1 Market Size and Overview
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.2 Key Vendor Ranking 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Accelrys Inc.
19.1.1 Business Overview
19.1.2 Business Segmentation
19.1.3 Key Information
19.1.4 Sales by Region
19.1.5 SWOT Analysis
19.2 Certara L.P.
19.2.1 Business Overview
19.2.2 Business Segmentation
19.2.3 Key Information
19.2.5 SWOT Analysis
19.3 Schrodinger Llc
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
19.4 Simulation Plus Inc.
19.4.1 Business Overview
19.4.2 Business Segmentation
19.4.3 Key Information
19.4.4 Sales by Region
19.4.5 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Market Segmentation
Exhibit 3: Market Segmentation by Application
Exhibit 4: Market Segmentation by Geography
Exhibit 5: Global Biosimulation Market 2013-2018 (US$ billion)
Exhibit 6: Global Biosimulation Market Segmentation by Application
Exhibit 7: Global Biosimulation Market Segmentation by Application 2013
Exhibit 8: Global Biosimulation Market Segmentation by Approach to Model Development
Exhibit 9: Global Biosimulation Market Segmentation by Scale of Biosimulation
Exhibit 10: Global Biosimulation Market Segmentation by Geography 2013
Exhibit 11: Global Biosimulation Market Segmentation by Geography 2013-2018 (percent)
Exhibit 12: Biosimulation Market in North America 2013-2018 (US$ million)
Exhibit 13: Biosimulation Market in Europe 2013-2018 (US$ million)
Exhibit 14: Biosimulation Market in APAC 2013-2018 (US$ million)
Exhibit 15: Biosimulation Market in ROW 2013-2018 (US$ million)
Exhibit 16: Business Segmentation of Accelrys Inc.
Exhibit 17: Sales by Region of Accelrys Inc. 2012
Exhibit 18: Business Segmentation of Certara L.P.
Exhibit 19: Business Segmentation of Schrodinger Llc
Exhibit 20: Business Segmentation of Simulation Plus Inc.
Exhibit 21: Sales by Region of Simulation Plus Inc. 2012
Commenting on the report, an analyst from the team said: “The Global Biosimulation market is witnessing increasing collaborations and partnerships between vendors. Such collaborations are aiding innovation in the market. For instance, Genedata is collaborating with Insilico Biotechnology AG, which is a Germany-based provider of software and solutions for the simulation of living cells, to support life science companies in improving and enhancing their biotechnological production methods. Additionally, a number of vendors in the Global Biosimulation market collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise software, signed a three-year agreement with Pfizer Inc., a pharmaceutical company, for the use of its products such as, modeling and simulation software, by Pfizer's researchers worldwide.”
According to the report, one of the most important drivers is the reduction in the drug discovery and development costs of pharmaceutical companies as a result of deploying biosimulation software solutions during the R&D process. Since such software brings about an understanding of clinical outcomes before human trials, their use adds immense value to pharmaceutical companies involved in the R&D of drugs, and helps companies reduce costs.
Further, the report states that one of the major challenges in the market is the high R&D costs associated with the development of biosimulation software. Several biosimulation models offer a virtual patient population to aid the development and testing of drugs, but these models are constructed using a large amount of data, which increases costs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Accelrys Inc.
- Certara L.P.
- Schrodinger Llc. and Simulation Plus Inc.
- Advanced Chemistry Development Inc.
- Archimedes Inc.
- Bayer Technology Services
- Biomed Simulation Inc.
- Chemical Computing Group Inc.
- Compugen Ltd.
- Entelos Inc.
- Genedata AG
- Immunetrix Inc.
- InhibOx Ltd.
- INOSIM Software GmbH
- In Silico Biosciences Inc.
- Insilico Biotechnology AG
- LeadInvent Technologies Pvt. Ltd.
- Leadscope Inc.
- Molecular Knowledge Systems Inc.
- Nimbus Discovery Llc
- OpenEye Scientific Software Inc.
- Optimata Inc.
- Physiomics Plc
- Rhenovia Pharma SAS
- Synergix Ltd.
- and Vascular Sciences.